A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant gain of 14.81% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 33.16%. Over the past 30 days, the price of BPMC has leaped by -4.04%. And in the last five days, it has fallen by -6.85%.
Blueprint Medicines Corp ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $121.90 on 07/16/24, while the lowest value for the same period was recorded at $43.89 on 10/25/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of BPMC Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Blueprint Medicines Corp’s current trading price is -13.12% away from its 52-week high, while its distance from the 52-week low is 141.29%. The stock’s price range during this period has varied between$43.89 and $121.90. The Blueprint Medicines Corp’s shares, which operate in the Healthcare, saw a trading volume of around 1.25 million for the day, a figure considerably higher than their average daily volume of 0.63 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Blueprint Medicines Corp (BPMC) has experienced a quarterly rise of 11.64% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 6.63B and boasts a workforce of 655 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 101.75, with a change in price of +14.52. Similarly, Blueprint Medicines Corp recorded 654,634 in trading volume during the last 100 days, posting a change of +15.73%.
BPMC’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BPMC stands at 1.92. Similarly, the long-term debt-to-equity ratio is also 1.64.
BPMC Stock Stochastic Average
Blueprint Medicines Corp’s raw stochastic average for the past 50 days is presently 34.58%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 34.58%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 16.33% and 16.80%, respectively.
